```html

Kernicterus (Chronic)

What is Kernicterus (Chronic)?

Kernicterus is a rare but severe form of bilirubin‑induced brain injury that occurs when unconjugated (indirect) bilirubin crosses the blood‑brain barrier and deposits in the basal ganglia, brainstem nuclei, and cerebellum. When the condition persists beyond the newborn period, it is referred to as chronic kernicterus. The injury is permanent, leading to a spectrum of neurological deficits that can include movement disorders, hearing loss, visual impairment, cognitive delay, and dental enamel defects. It is most commonly recognized in infancy, but the long‑term sequelae may be evaluated years later, which is why it is labeled “chronic.”

Unconjugated bilirubin is normally bound to albumin and transported to the liver for conjugation and excretion. In newborns, especially preterm infants, the liver’s conjugating enzymes (UGT1A1) are immature, and the blood‑brain barrier is more permeable. When bilirubin levels rise faster than they can be cleared, the excess free bilirubin can infiltrate the brain, causing the irreversible damage seen in kernicterus.

Sources: Mayo Clinic, Mayo Clinic; National Institutes of Health (NIH), NIH Review.

Common Causes

Most cases of chronic kernicterus stem from conditions that dramatically increase unconjugated bilirubin or impair its elimination. The most frequent contributors are listed below:

• Hemolytic disease of the newborn (HDN) – typically due to Rh or ABO incompatibility.
<
• G6PD deficiency – an inherited enzyme defect that predisposes red blood cells to oxidative damage.
• Hereditary spherocytosis – abnormal red‑cell membranes cause chronic hemolysis.
• Crigler‑Najjar syndrome type I – a rare autosomal‑recessive disorder with absent UGT1A1 activity.
• Breast‑milk jaundice – increased enterohepatic recycling of bilirubin in some breast‑fed infants.
• Prematurity – immature liver enzymes and thinner blood‑brain barrier.
• Sepsis or severe infections – can precipitate hemolysis and impair hepatic function.
• Medication‑induced hyperbilirubinemia – drugs such as sulfonamides, ceftriaxone, or certain antivirals.
• Genetic polymorphisms in UGT1A1 (Gilbert or mild Crigler‑Najjar variants) – may exacerbate jaundice when combined with other risk factors.
• Metabolic disorders – e.g., hypothyroidism or galactosemia that affect bilirubin metabolism.

Associated Symptoms

Because kernicterus reflects central nervous system injury, the clinical picture includes both acute signs of severe hyperbilirubinemia and chronic neurologic sequelae. Commonly reported findings are:

• High‑pitch or “machine‑like” cry in newborns.
• Lethargy, poor feeding, or difficulty waking.
• Hypotonia progressing to spasticity (especially in the upper limbs).
• Movement disorders such as choreoathetoid movements or dystonia.
• Auditory neuropathy – hearing loss that may be detected on newborn hearing screens.
• Visual disturbances, including nystagmus or reduced visual acuity.
• Dental enamel hypoplasia (characteristic “yellow‑brown” staining of teeth).
• Cognitive delays, learning difficulties, and behavioral problems.
• Seizures in severe or unrecognized cases.

When to See a Doctor

Prompt medical evaluation is critical whenever a newborn shows any sign of rising bilirubin or neurologic change. Seek care immediately if you notice:

• Yellowing of the skin or eyes that spreads beyond the face.
• A high‑pitched, inconsolable cry or “fussy” behavior.
• Lethargy, poor sucking, or inability to stay awake for feeds.
• Any decrease in muscle tone or abnormal movements.
• Signs of dehydration (dry mouth, sunken fontanelle, reduced urine output).
• Persistent jaundice after 2 weeks of age in a term infant or after 1 week in a preterm infant.

If you are caring for an infant with any of the risk factors listed above (e.g., blood‑type incompatibility, prematurity, known hemolytic disorder), schedule a follow‑up with your pediatrician within 24 hours of any jaundice concern.

Diagnosis

Diagnosing chronic kernicterus involves a combination of clinical assessment, laboratory testing, and imaging.

1. Laboratory Evaluation

• Serum total & direct bilirubin – to confirm unconjugated hyperbilirubinemia.
• Complete blood count (CBC) and reticulocyte count – evaluate hemolysis.
• Blood type & Coombs test – identify maternal‑fetal incompatibility.
• G6PD assay – screen for enzymatic deficiency.
• Liver function tests (ALT, AST, GGT) – assess hepatic injury.
• Genetic testing – for UGT1A1 mutations (Crigler‑Najjar, Gilbert) if hereditary causes are suspected.

2. Neuro‑Imaging

• MRI of the brain – T1‑weighted images often reveal hyperintensity in the basal ganglia, a hallmark of kernicterus.
• Ultrasound – may be used initially in the NICU to assess intracranial hemorrhage or hydrocephalus.

3. Auditory & Visual Testing

• Automated auditory brainstem response (ABR) or otoacoustic emissions (OAE) to detect hearing impairment.
• Ophthalmologic exam for nystagmus, strabismus, or optic nerve changes.

4. Developmental Assessment

Standardized scales (Bayley Scales of Infant Development, Denver Developmental Screening Test) are used to document cognitive and motor delays over time.

Treatment Options

Because the brain damage from chronic kernicterus is permanent, treatment focuses on preventing further injury, managing complications, and optimizing quality of life.

Acute Management (to prevent progression)

• Phototherapy – blue‑light converts unconjugated bilirubin into water‑soluble isomers that can be excreted without conjugation.
• Exchange transfusion – indicated when bilirubin levels exceed thresholds (e.g., >25 mg/dL in term infants) or when neurologic signs appear despite phototherapy.
• Intravenous immunoglobulin (IVIG) – may reduce hemolysis in iso‑immune hemolytic disease.
• Intravenous fluids & albumin – maintain renal perfusion and bind free bilirubin.

Long‑Term Management

• Neurologic rehabilitation – physical, occupational, and speech therapy to address motor and communication deficits.
• Antiepileptic drugs – for seizure control if needed.
• Hearing aids or cochlear implants – for permanent auditory neuropathy.
• Dental care – early referral to pediatric dentistry to manage enamel hypoplasia and prevent caries.
• Educational support – individualized education plans (IEPs) for school‑aged children.
• Psychosocial counseling – for families coping with chronic disability.

Home Care & Supportive Measures

• Maintain a regular feeding schedule to promote bilirubin excretion via stool.
• Ensure adequate hydration – especially during illnesses that increase fever or reduce intake.
• Monitor temperature and avoid overheating, which can increase bilirubin production.
• Keep follow‑up appointments with neurology, audiology, and ophthalmology.

Prevention Tips

Because many risk factors are identifiable before or shortly after birth, targeted prevention can markedly reduce the incidence of kernicterus.

• Universal newborn bilirubin screening – transcutaneous or serum bilirubin measurement before discharge.
• Early and adequate phototherapy – start promptly when bilirubin exceeds age‑specific nomograms.
• Blood‑type screening of mother and newborn – to anticipate allo‑immune hemolysis and administer RhIg when indicated.
• Screen for G6PD deficiency in at‑risk populations – especially in males of Mediterranean, African, or Asian descent.
• Educate parents on “jaundice watch” – signs to look for and when to seek care.
• Breast‑feeding support – encourage frequent feeds; consider temporary supplementation if bilirubin rises rapidly.
• Avoid drugs that displace bilirubin from albumin – e.g., sulfonamides, high‑dose aspirin, certain antibiotics.
• Manage infections aggressively – sepsis can precipitate hemolysis and hepatic dysfunction.
• Genetic counseling for families with known hereditary bilirubin disorders.

Emergency Warning Signs

If any of the following occur, seek emergency medical attention (call 911 or go to the nearest Emergency Department) immediately:

• Rapidly increasing jaundice that spreads to the abdomen or limbs.
• Very high‑pitched or unresponsive crying.
• Extreme lethargy, inability to wake for feeds, or “floppy” appearance.
• Seizures or abnormal rhythmic movements.
• Feeding refusal accompanied by signs of dehydration (dry mouth, sunken fontanelle).
• Sudden change in muscle tone – becoming stiff or floppy.

Early intervention can stop bilirubin from reaching neurotoxic levels and prevent irreversible damage.

---

Sources: Mayo Clinic; CDC – Neonatal Jaundice; National Institutes of Health (NIH); World Health Organization (WHO); Cleveland Clinic – Kernicterus.

```